Managers / Q1 2021 · view latest →
venBio Partners LLC
CIK 0001776382 · 1700 OWENS STREET, SUITE 595, SAN FRANCISCO, CA, 94158 · 415-522-0100
Summary
Venbio Partners LLC reported $1.1B in U.S.-listed holdings across 8 positions for Q1 2021.
The portfolio is heavily concentrated: ALXO alone accounts for 68.0% of reported value.
Compared with Q4 2020, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 87.7% · $923M
- Other · 12.2% · $128M
- ADR · 0.1% · $1M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| PHARVARIS N V | NEW | +2.30M | 2.30M | +$64M | $64M |
| VRNAVERONA PHARMA PLC | TRIMMED | −37.2K | 161.9K | −$41,000 | $1M |
| ALXOALX ONCOLOGY HLDGS INC | HELD | +0 | 9.70M | −$121M | $715M |
| HRMYHARMONY BIOSCIENCES HLDGS IN | HELD | +0 | 3.50M | −$11M | $116M |
| CHECKMATE PHARMACEUTICALS IN | HELD | +0 | 3.67M | −$9M | $45M |
| AKROAKERO THERAPEUTICS INC | HELD | +0 | 2.44M | +$8M | $71M |
| APELLIS PHARMACEUTICALS INC | HELD | +0 | 490.5K | −$7M | $21M |
| METACRINE INC | HELD | +0 | 3.06M | −$5M | $19M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2021
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | ALXOALX ONCOLOGY HLDGS INChistory → | COM | 67.97% | $715M | 9.70M |
| 2 | HRMYHARMONY BIOSCIENCES HLDGS INhistory → | COM | 11.00% | $116M | 3.50M |
| 3 | AKROAKERO THERAPEUTICS INChistory → | COM | 6.74% | $71M | 2.44M |
| 4 | PHARVARIS N V | COM | 6.12% | $64M | 2.30M |
| 5 | CHECKMATE PHARMACEUTICALS IN | COM | 4.24% | $45M | 3.67M |
| 6 | APELLIS PHARMACEUTICALS INC | COM | 2.00% | $21M | 490.5K |
| 7 | METACRINE INC | COM | 1.80% | $19M | 3.06M |
| 8 | VRNAVERONA PHARMA PLC | SPONSORED ADS | 0.13% | $1M | 161.9K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $281M | 6 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $216M | 6 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $176M | 6 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $115M | 6 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $124M | 7 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $171M | 7 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $194M | 6 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $232M | 6 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $282M | 5 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $667M | 7 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $353M | 8 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $276M | 7 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $180M | 6 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $323M | 7 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $432M | 8 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $351M | 9 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $451M | 10 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $555M | 9 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.0B | 9 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $847M | 10 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.1B | 8 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.1B | 7 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $658M | 8 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $120M | 4 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $38M | 3 | May 26, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $233M | 6 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2019 | $211M | 6 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2019 | $225M | 6 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2019 | $123M | 4 | May 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.